Fungal Infection News and Research

RSS

Immtech and BioAlliance sign agreement on Pafuramidine for African sleeping sickness

Immtech Pharmaceuticals has announced that the Company has granted an exclusive license to BioAlliance Pharma SA to commercialize Immtech's oral drug, pafuramidine maleate (pafuramidine), in Europe for the treatment of pneumocystis pneumonia (PCP) in AIDS patients and for the treatment of Human African trypanosomiasis, also known as African sleeping sickness.

5 Dec 2007

Inhaled immune system stimulant launches immune response in lungs to wipe out lethal infections

An inhaled immune system stimulant protects mice against lethal pneumococcal pneumonia and other deadly bacterial, viral and fungal infections of the lungs, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports at a major scientific meeting.

4 Dec 2007

Experimental gene therapy trial for arthritis allowed to resume

Trials in the U.S. of a controversial and experimental gene therapy have been given the green light to resume following the tragic death of a volunteer in July.

27 Nov 2007

Immtech receives $5.1 million to tackle trypanosomiasis and leishmania

Immtech Pharmaceuticals, Inc. has announced that it has received $5.1 million from a scientific consortium led by the University of North Carolina at Chapel Hill (UNC), which received funds from The Bill & Melinda Gates Foundation, to develop drugs for fighting African sleeping sickness (trypanosomiasis) and leishmania.

6 Nov 2007

Gamma interferon could aid fight against fungal infections

Interferon, the "superhero" cure for viral infections, may be a strong weapon in the battle against fungal infections in immunocompromised patients, according to an article in the November issue of Microbiology Today.

1 Nov 2007

How Candida albicans transforms from its normally benign form into life-threatening form

Researchers at the Agency for Science, Technology and Research's (A*STAR) Institute of Molecular and Cell Biology (IMCB) have discovered new molecular mechanisms that provide a more detailed understanding of how the normally benign Dr. Jekyll-like fungus known as Candida albicans transforms into a serious and often life-threatening Mr. Hyde-like form.

4 Oct 2007

Wal-Mart adds 11 generic drugs to discounted prescription drug program

Wal-Mart Stores on Thursday announced that it will begin selling eight additional generic drugs for $4 per 30-day prescription and several family-planning drugs for $9, USA Today reports (Appleby, USA Today, 9/28).

2 Oct 2007

FDA approves Lamisil for child treatment of scalp ringworm

The U.S. Food and Drug Administration announced the approval of Lamisil Oral Granules for the treatment of tinea capitis, a fungal infection of the scalp, in children ages 4 years and older.

29 Sep 2007

Discovery of cause of Job's syndrome

The rare immunodeficiency disorder known as Job's syndrome is caused by a specific genetic mutation that both overstimulates and understimulates the human immune system, leading to harmful bacterial and fungal infections and the physical features characteristic of the syndrome, according to two independent groups of scientists, one from the National Institutes of Health (NIH) and the other from the Tokyo Medical and Dental University.

20 Sep 2007

Pregnancy may slow AIDS progression

A new study may help put to rest fears that pregnancy accelerates progression to full-blown AIDS in women with HIV receiving antiretroviral therapy.

20 Sep 2007

FDA warns against use of red yeast rice products promoted as high cholesterol treatment

The U.S. Food and Drug Administration is warning consumers not to buy or eat three red yeast rice products promoted and sold on Web sites.

12 Aug 2007

Actavis launches Terbinafine hydrochloride tablets in the U.S.

Actavis Group has announced that it has launched Terbinafine hydrochloride tablets in the U.S. Distribution of the product will commence immediately.

10 Jul 2007

New working principle in cancer treatment

Due to defects in chromosomal distribution, a majority of tumor cells would not be able to survive were it not for a trick that cancer cells have developed to avoid this chaos in the genetic material.

5 Jul 2007

New compound kills fungal pathogens

A new mechanism to attack hard-to-treat fungal infections has been revealed by scientists from the biotech company Anacor Pharmaceuticals Inc., California, and the European Molecular Biology Laboratory (EMBL) outstation in Grenoble, France.

23 Jun 2007

Anacor finds novel mechanism for lead anti-fungal drug, AN2690

Anacor Pharmaceuticals, a privately held pharmaceutical company, has announced that the journal Science will publish results of research that details how AN2690, the company's lead clinical candidate, kills fungal cells by interfering with synthesis of a specific protein required for fungal growth.

23 Jun 2007

Drug for toenail fungus also blocks angiogenesis

Researchers at Johns Hopkins have discovered to their surprise that a drug commonly used to treat toenail fungus can also block angiogenesis, the growth of new blood vessels commonly seen in cancers.

30 Apr 2007

One species of insect shown to deliberately cultivate bacteria in its antennae

Bacteria live in, on and around us and other organisms with sometimes very beneficial results.

2 Apr 2007

Antifungal drug kills tuberculosis bug

Scientists hoping to find new treatments for one of the world's most deadly infectious diseases say drugs used to treat common fungal infections may provide the answer.

From The University of Manchester 12 Mar 2007

New drug delivery method incorporates drug molecules in fat

Devastating blood-borne fungal infections that can be lethal for HIV/AIDS, cancer, and organ transplant patients may be treated more successfully, thanks to a new drug delivery method developed by researchers at the University of British Columbia in Vancouver.

5 Mar 2007

Procalcitonin helps predict prognosis among those with peritonitis

Monitoring blood levels of a compound known as procalcitonin in patients with peritonitis (a serious intra-abdominal infection) could help identify patients at increased risk of organ failure and death, according to a report in the February issue of Archives of Surgery.

20 Feb 2007